Natural killer (NK) cells and anti‐tumor therapeutic mAb: unexplored interactions
[摘要] Tumor‐targetingmAbarewidelyusedinthetreatmentofavarietyofsolidandhematopoietictumorsandrepresentthefirstimmunotherapeuticapproachsuccessfullyarrivedtotheclinic.Nevertheless,theroleofdistinctimmunemechanismsincontributingtotheirtherapeuticefficacyisnotcompletelyunderstoodandmayvarydependingontumor‐orantigen/antibody‐dependentcharacteristics.Availabilityofnext‐generation,engineered,tumor‐targetingmAb,optimizedintheircapabilitytorecruitselectedimmuneeffectors,re‐enforcestheneedforadeeperunderstandingofthemechanismsunderlyinganti‐tumormAbfunctionality.NKcellsparticipatewithamajorroletoinnateanti‐tumorresponses,byexertingcytotoxicactivityandproducingavastarrayofcytokines.AstheCD16(low‐affinityFcγRIIIA)‐activatingreceptorisexpressedonthemajorityofNKcells,itseffectorfunctionscanbeideallyrecruitedagainsttherapeuticmAb‐opsonizedtumorcells.TheexactroleofNKcellsindeterminingtherapeuticefficacyoftumor‐targetingmAbisstillunclearandmuchsoughtafter.Thisknowledgewillbeinstrumentaltodesigninnovativecombinationschemeswithnewlyvalidatedimmunomodulatoryagents.WewillsummarizewhatisknownabouttheroleofNKcellsintherapeuticanti‐tumormAbtherapy,withparticularemphasisonRTXchimericanti‐CD20mAb,thefirstoneusedinclinicalpracticefortreatingBcellmalignancies...
[发布日期] [发布机构]
[效力级别] [学科分类] 生理学
[关键词] ADCC;chemoimmunotherapy;FcγRs;rituximab [时效性]
